Cargando…
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in health...
Autores principales: | Mehta, Sudhir, Bhandari, Sudhir, Mehta, Shaurya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836824/ https://www.ncbi.nlm.nih.gov/pubmed/32777441 http://dx.doi.org/10.1016/j.jgar.2020.07.022 |
Ejemplares similares
-
Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen
por: Pareek, Anil, et al.
Publicado: (2020) -
Cautious interpretation of antiphospholipid antibodies in COVID-19
por: Mehta, Sudhir, et al.
Publicado: (2020) -
Brain autopsies in fatal COVID-19 and postulated pathophysiology: more puzzling than a Rubik’s cube
por: Mehta, Sudhir, et al.
Publicado: (2021) -
Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection
por: Yadav, Reetika Malik, et al.
Publicado: (2021) -
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
por: Rajasingham, Radha, et al.
Publicado: (2020)